Abstract
Sparfloxacin (SPFX) is a newly developed oral pyridonecarboxilic acid antimicrobial agent. Among the current quinolone derivatives, SPFX is characterized as the most potent antimicrobial with a broad spectrum of activity and a long plasma elimination life. SPFX has also the advantage of extensive tissue penetration.
1) The in vitro postantibiotic effect of SPFX by exposing isolates at the 2 to 4 fold MIC for 1 to 2 hrs was 0.8 to 2.1 hrs for Escherichia coli, 2. 2 to 3. 2 hrs for Klebsiella pneumoniae, and 1.9 to 2.6 hrs for Pseudomonas aeruginosa. The in vitro effective regrowth time (ERT) of SPFX was longer than that of ofloxacin and enoxacin. In Klebsiella pnemoniae BK in a neutropenic mouse thigh infection model, the change in viable counts at 24 hrs was almost the same with dosage regimens of 2mg/kg twice-a-day, and 4mg/kg once-a-day.
2) SPFX was administered to 12 patients mainly with respiratory tract infections, the efficacy rate being 88% with efficient bacterial eradication. The dose regimen of 300mg once-a-day was better than that of 150mg twice-a-day in terms of the rate of “excellent” and the safety.
